Contributions
Abstract: P1789
Type: Poster Sessions
Abstract Category: N/A
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Although the cause of MS is still unclear, many findings point toward the crosstalk between coagulation and inflammation due to the presence of specific antibodies, which act as procoagulant factors leading to thrombosis, in a condition characterized clinically as the Antiphospholipid Syndrome (APS). Taking into account the overlap of symptoms in MS and APS, particularly venous thromboembolism, the identification of antibodies against procoagulant and/or anticoagulant serine proteases namely Factor VIIa (FVIIa), Factor Xa (FXa) and plasmin should be considered. Furthermore, the presence of antibodies against the subunits of the excitatory NMDA receptor (NMDAR) has been recently suggested as a candidate biomarker in MS with only a handful of studies examining this association. In the present study, we aim to evaluate the prevalence of antibodies against procoagulant and/or anticoagulant serine proteases which have not yet been investigated in MS, in addition to antibodies against the NR2B subunit of NMDAR.
Methods: Serum samples from 100 MS patients [83 Relapse-Remitting patients (RRMS), 13 Secondary Progressive (SPMS) and 4 Primary Progressive patients (PPMS)] and 60 age and gender matched HCs were analyzed for IgG antibodies against FVIIa, FXa and plasmin, as well as against the NR2B subunit of NMDAR using ELISA.
Results: Increased levels of IgG anti-FVIIa were detected in MS patients compared to HC (3.2% and 0% respectively, p< 0.05). Additionally, anti-Xa were associated with 4% of MS individuals in comparison to none of the HC (p< 0.05). Likewise, IgG anti-plasmin were detected in MS patients (3.2%) compared to none of HCs indicating a significant association of antibodies with MS (p< 0.001). Interestingly, anti-NR2B were identified in 6% of MS patients in comparison to 1% of HCs (p< 0.05). Of equal importance is the finding that patients with RRMS had the higher levels of antibodies compared to other types of MS.
Conclusion: This study demonstrated increased prevalence of antibodies against various coagulation factors and against the NMDAR subunit in the serum of MS patients. These findings may prove valuable in future studies, to evaluate possible mechanisms involving these antibodies and in clarifying their role as potential risk factors in MS.
Disclosure: Maria Hadjiagapiou: nothing to disclose
George Krashias: nothing to disclose
Christina Christodoulou: nothing to disclose
Marios Pantiazris: nothing to disclose
Anastasia Lambrianides: nothing to disclose
Abstract: P1789
Type: Poster Sessions
Abstract Category: N/A
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Although the cause of MS is still unclear, many findings point toward the crosstalk between coagulation and inflammation due to the presence of specific antibodies, which act as procoagulant factors leading to thrombosis, in a condition characterized clinically as the Antiphospholipid Syndrome (APS). Taking into account the overlap of symptoms in MS and APS, particularly venous thromboembolism, the identification of antibodies against procoagulant and/or anticoagulant serine proteases namely Factor VIIa (FVIIa), Factor Xa (FXa) and plasmin should be considered. Furthermore, the presence of antibodies against the subunits of the excitatory NMDA receptor (NMDAR) has been recently suggested as a candidate biomarker in MS with only a handful of studies examining this association. In the present study, we aim to evaluate the prevalence of antibodies against procoagulant and/or anticoagulant serine proteases which have not yet been investigated in MS, in addition to antibodies against the NR2B subunit of NMDAR.
Methods: Serum samples from 100 MS patients [83 Relapse-Remitting patients (RRMS), 13 Secondary Progressive (SPMS) and 4 Primary Progressive patients (PPMS)] and 60 age and gender matched HCs were analyzed for IgG antibodies against FVIIa, FXa and plasmin, as well as against the NR2B subunit of NMDAR using ELISA.
Results: Increased levels of IgG anti-FVIIa were detected in MS patients compared to HC (3.2% and 0% respectively, p< 0.05). Additionally, anti-Xa were associated with 4% of MS individuals in comparison to none of the HC (p< 0.05). Likewise, IgG anti-plasmin were detected in MS patients (3.2%) compared to none of HCs indicating a significant association of antibodies with MS (p< 0.001). Interestingly, anti-NR2B were identified in 6% of MS patients in comparison to 1% of HCs (p< 0.05). Of equal importance is the finding that patients with RRMS had the higher levels of antibodies compared to other types of MS.
Conclusion: This study demonstrated increased prevalence of antibodies against various coagulation factors and against the NMDAR subunit in the serum of MS patients. These findings may prove valuable in future studies, to evaluate possible mechanisms involving these antibodies and in clarifying their role as potential risk factors in MS.
Disclosure: Maria Hadjiagapiou: nothing to disclose
George Krashias: nothing to disclose
Christina Christodoulou: nothing to disclose
Marios Pantiazris: nothing to disclose
Anastasia Lambrianides: nothing to disclose